The Angelo King Medical Research Center, DLSMHSI Research Division, has been selected by the National Institutes of Health (NIH) in the United States as one of 101 clinical research sites (CRSs) responsible for implementing the scientific agenda of the NIH HIV/AIDS clinical research networks. The CRSs are funded by NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The site will be under the umbrella of Emory HIV Clinical Trials Unit (CTU) in Atlanta, Georgia which was one of the 35 CTUs selected for this recompetition. The seven-year award to Emory has an expected funding of $12.5 million.
The DLSMHSI CRS will conduct clinical trials within The AIDS Clinical Trials Group (ACTG).
In November 2016, the research division of DLSMHSI was identified as a protocol-specific site for the AIDS Clinical Trials Group (ACTG) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) networks phase 3 international multicenter trial entitled “Protecting Households On Exposure to Newly Diagnosed Index Multidrug-resistant Tuberculosis Patients (PHOENIX)”.
The research activities of the NIH HIV clinical trials networks also include the treatment and prevention of other infectious diseases, including tuberculosis and hepatitis, which are the most significant co-infections for people living with, or at risk for, HIV.
The DLSMHSI CRS is directed by Dr. Melchor Frias, a professor in Pediatrics and clinical epidemiologist, DLSMHSI College of Medicine; and Dr. Maria Tarcela Gler, an Infectious Disease Specialist and an MDR-TB clinician.
The Emory HIV CTU is directed by two principal investigators, Dr. Jeffrey Lennox, professor of medicine in infectious diseases and associate dean for clinical research at Emory University School of Medicine; and Dr. Carlos del Rio, professor of medicine in infectious diseases and executive associate dean for Emory School of Medicine at Grady Health System and co-Director of the Emory Center for AIDS Research.
"We are very excited about the important clinical trials work this grant will continue to allow us to pursue," says Lennox.
"Our existing Emory CTU has been very successful in conducting HIV clinical trials, but our partnerships in Mexico and the Philippines expand our reach to two key international sites and will allow us to move forward with new research that could make a significant impact on this still challenging disease," says del Rio.
More information about the NIH HIV Clinical Trials Networks here.